NASDAQ:ARPO - Aerpio Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $2.75
  • Forecasted Upside: 61.76 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.70
▼ -0.04 (-2.30%)
1 month | 3 months | 12 months
Get New Aerpio Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ARPO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ARPO

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$2.75
▲ +61.76% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Aerpio Pharmaceuticals in the last 3 months. The average price target is $2.75, with a high forecast of $4.00 and a low forecast of $1.50. The average price target represents a 61.76% upside from the last price of $1.70.
Buy
The current consensus among 2 contributing investment analysts is to buy stock in Aerpio Pharmaceuticals. This rating has held steady since December 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/11/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/10/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/9/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/7/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/5/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/4/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/2/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/4/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/14/2020HC WainwrightReiterated RatingNeutral$2.00 ➝ $1.50High
i
Rating by Yi Chen at HC Wainwright
12/9/2020BTIG ResearchInitiated CoverageBuy$4.00High
i
9/17/2020HC WainwrightReiterated RatingHold$2.00High
i
Rating by Yi Chen at HC Wainwright
8/13/2020HC WainwrightBoost Price TargetNeutral$1.50 ➝ $2.00High
i
Rating by Yi Chen at HC Wainwright
6/25/2020HC WainwrightBoost Price TargetNeutral$1.00 ➝ $1.50High
i
Rating by Yi Chen at HC Wainwright
5/28/2020HC WainwrightReiterated RatingHold$1.00High
i
Rating by Yi Chen at HC Wainwright
2/10/2020HC WainwrightReiterated RatingHold$1.00Low
i
Rating by Yi Chen at HC Wainwright
10/21/2019HC WainwrightSet Price TargetHold$1.00Low
i
Rating by Yi Chen at HC Wainwright
8/9/2019HC WainwrightReiterated RatingHold$1.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
6/12/2019HC WainwrightReiterated RatingNeutralLow
i
Rating by Y. Chen at HC Wainwright
6/12/2019HC WainwrightInitiated CoverageNeutral$1.00Low
i
Rating by Ram Selvaraju at HC Wainwright
5/10/2019HC WainwrightReiterated RatingHoldHigh
i
Rating by Ram Selvaraju at HC Wainwright
4/5/2019HC WainwrightReiterated RatingHoldLow
i
Rating by Ram Selvaraju at HC Wainwright
3/19/2019HC WainwrightDowngradeBuy ➝ NeutralHigh
i
Rating by Ram Selvaraju at HC Wainwright
3/18/2019GuggenheimDowngradeBuy ➝ NeutralHigh
i
3/18/2019National SecuritiesDowngradeBuy ➝ NeutralN/A
i
3/6/2019HC WainwrightReiterated RatingBuyLow
i
Rating by Ram Selvaraju at HC Wainwright
3/5/2019Cantor FitzgeraldSet Price TargetBuy$8.00Low
i
Rating by Eliana Merle at Cantor Fitzgerald
2/11/2019Cantor FitzgeraldSet Price TargetBuy$8.00Low
i
Rating by Eliana Merle at Cantor Fitzgerald
1/18/2019Cantor FitzgeraldReiterated RatingOverweightMedium
i
Rating by E. Merle at Cantor Fitzgerald
1/18/2019Cantor FitzgeraldInitiated CoverageOverweight$8.00High
i
11/8/2018HC WainwrightSet Price TargetBuy$9.00Low
i
Rating by Ram Selvaraju at HC Wainwright
10/29/2018HC WainwrightSet Price TargetBuy$9.00Low
i
Rating by Ram Selvaraju at HC Wainwright
9/19/2018GuggenheimInitiated CoverageBuy$10.00High
i
8/15/2018HC WainwrightSet Price TargetBuy$9.00High
i
Rating by Ram Selvaraju at HC Wainwright
7/23/2018Needham & Company LLCInitiated CoverageBuy$10.00Low
i
4/18/2018HC WainwrightInitiated CoverageBuy$10.00High
i
(Data available from 3/4/2016 forward)
Aerpio Pharmaceuticals logo
Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing compounds for the treatment of ocular diseases and diabetic complications. The company's lead product candidate is razuprotafib, a small molecule activator of the Tie2 pathway, which completed the Phase IIb clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, which is in a Phase 1b clinical trial for the treatment of inflammatory bowel disease; and bispecific antibody for the treatment for wet age-related macular degeneration and DME through intravitreal injection. Aerpio Pharmaceuticals, Inc. has a collaboration with Quantum Leap Healthcare Collaborative for the evaluation of razuprotafib in the treatment of acute respiratory distress syndrome in adult patients with moderate to severe COVID-19. The company is headquartered in Cincinnati, Ohio.
Read More

Today's Range

Now: $1.70
$1.60
$1.79

50 Day Range

MA: $1.61
$1.18
$2.06

52 Week Range

Now: $1.70
$0.42
$2.31

Volume

1,431,956 shs

Average Volume

2,436,291 shs

Market Capitalization

$80.09 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.02

Frequently Asked Questions

What sell-side analysts currently cover shares of Aerpio Pharmaceuticals?

The following sell-side analysts have issued stock ratings on Aerpio Pharmaceuticals in the last year: BTIG Research, HC Wainwright, and Zacks Investment Research.
View the latest analyst ratings for ARPO.

What is the current price target for Aerpio Pharmaceuticals?

2 Wall Street analysts have set twelve-month price targets for Aerpio Pharmaceuticals in the last year. Their average twelve-month price target is $2.75, suggesting a possible upside of 61.8%. BTIG Research has the highest price target set, predicting ARPO will reach $4.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $1.50 for Aerpio Pharmaceuticals in the next year.
View the latest price targets for ARPO.

What is the current consensus analyst rating for Aerpio Pharmaceuticals?

Aerpio Pharmaceuticals currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ARPO will outperform the market and that investors should add to their positions of Aerpio Pharmaceuticals.
View the latest ratings for ARPO.

What other companies compete with Aerpio Pharmaceuticals?

How do I contact Aerpio Pharmaceuticals' investor relations team?

Aerpio Pharmaceuticals' physical mailing address is 9987 CARVER ROAD, CINCINNATI OH, 45242. The company's listed phone number is 513 985 1920 and its investor relations email address is [email protected] The official website for Aerpio Pharmaceuticals is www.aerpio.com.